{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:27:44Z","timestamp":1776785264635,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinical-colorectal-cancer.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clcc.2024.05.009","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T16:21:00Z","timestamp":1717431660000},"page":"318-325.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum\/Gemcitabine Progression: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-5951","authenticated-orcid":false,"given":"Ioannis A.","family":"Voutsadakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Kokkali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Digklia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clcc.2024.05.009_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2024.05.009_bib0002","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"35","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.clcc.2024.05.009_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11523-022-00942-6","article-title":"Optimizing patient pathways in advanced biliary tract cancers: recent advances and a french perspective","volume":"18","author":"Neuzillet","year":"2023","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2024.05.009_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.clcc.2024.05.009_bib0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clcc.2024.05.009_bib0006","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2024.05.009_bib0007","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.clcc.2024.05.009_bib0008","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","article-title":"FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation","volume":"28","author":"Casak","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clcc.2024.05.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102049","article-title":"Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma","volume":"8","author":"Lamarca","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clcc.2024.05.009_bib0010","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Advanced biliary cancer working group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2024.05.009_bib0011","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.clcc.2024.05.009_bib0012","first-page":"S563","article-title":"Nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC \u2013 AIO-HEP-0116)","volume":"33","author":"a","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2024.05.009_bib0013","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17474124.2022.2047651","article-title":"Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY","volume":"16","author":"Rizzo","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clcc.2024.05.009_bib0014","article-title":"Second line FOLFOX chemotherapy for advanced biliary tract cancers pre-treated with cisplatin\/gemcitabine: a systematic review and meta-analysis","volume":"4","author":"Digklia","year":"2024","journal-title":"ESMO Gastrointest Cancer"},{"issue":"3","key":"10.1016\/j.clcc.2024.05.009_bib0015","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clcc.2024.05.009_bib0016","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2024.05.009_bib0017","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Abou-alfa GK. final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2024.05.009_bib0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"FOENIX-CCA2 study investigators. futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clcc.2024.05.009_bib0019","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.05.009_bib0020","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clcc.2024.05.009_bib0021","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.clcc.2024.05.009_bib0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1756-0500-5-52","article-title":"Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis","volume":"5","author":"Neyeloff","year":"2012","journal-title":"BMC Res Notes"},{"issue":"2","key":"10.1016\/j.clcc.2024.05.009_bib0023","doi-asserted-by":"crossref","DOI":"10.4322\/acr.2019.087","article-title":"FOLFIRI as second-line treatment of metastatic biliary tract cancer patients","volume":"9","author":"Caparica","year":"2019","journal-title":"Autops Case Rep"},{"issue":"2","key":"10.1016\/j.clcc.2024.05.009_bib0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3892\/mco.2021.2485","article-title":"Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers","volume":"16","author":"Allo","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2024.05.009_bib0025","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1111\/ajco.13599","article-title":"Combination chemotherapy with NAB\u00ae -paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study)","volume":"18","author":"Woodford","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2024.05.009_bib0026","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/bjc.2016.446","article-title":"Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients","volume":"116","author":"Kim","year":"2017","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.clcc.2024.05.009_bib0027","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1002\/ijc.33146","article-title":"AGEO (association des gastro-ent\u00e9rologues oncologues) investigators; GICO (Italian group of cholangiocarcinoma) investigators. fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer","volume":"147","author":"Neuzillet","year":"2020","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.clcc.2024.05.009_bib0028","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2024.05.009_bib0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","article-title":"A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin","volume":"119","author":"Zheng","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clcc.2024.05.009_bib0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaoncol.2020.6166","article-title":"Efficacy of capecitabine plus irinotecan vs irinotecan monotherapy as second-line treatment in patients with advanced gallbladder cancer: a multicenter phase 2 randomized clinical trial (GB-SELECT)","volume":"7","author":"Ramaswamy","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2024.05.009_bib0031","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4251\/wjgo.v12.i1.83","article-title":"Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers","volume":"12","author":"Mizrahi","year":"2020","journal-title":"World J Gastrointest Oncol"},{"issue":"9-10","key":"10.1016\/j.clcc.2024.05.009_bib0032","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/0284186X.2016.1191670","article-title":"Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers","volume":"55","author":"Sebbagh","year":"2016","journal-title":"Acta Oncol"},{"issue":"18","key":"10.1016\/j.clcc.2024.05.009_bib0033","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/cncr.29471","article-title":"Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the association des gastro-ent\u00e9rologues oncologues","volume":"121","author":"Brieau","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2024.05.009_bib0034","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clcc.2024.05.009_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clon.2023.12.005","article-title":"Is there room for liposomal irinotecan in biliary tract cancer? a meta-analysis of randomised trials","volume":"36","author":"Merz","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clcc.2024.05.009_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1293670","article-title":"FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy","volume":"13","author":"Roussot","year":"2023","journal-title":"Front Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:08:15Z","timestamp":1732723695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002824000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1533002824000549"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2024.05.009","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum\/Gemcitabine Progression: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2024.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}